Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

Posted on by

Porustobart in combination of toripalimab showed promising anti-tumor activity Porustobart in combination of toripalimab showed acceptable safety profile in HCC Porustobart in combination of toripalimab showed favorable PK/PD signature CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU,…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.